Heidi Móciková

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne et al. · Journal of Clinical Oncology · 2021 · 252 citations · Full text

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

Chan Y. Cheah, Anupkumar George, Eva Giné et al. · Annals of Oncology · 2013 · 130 citations · Full text

Prognostic Factors, Neuro-oncology, Lymphoid Neoplasia +4

ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R²‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma

Umberto Vitolo, Thomas E. Witzig, Randy D. Gascoyne et al. · Hematological Oncology · 2019 · 84 citations

Surgical Oncology, Cd20+ Abc-type Dlbcl, Immunodeficiencies +22

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

Kateřina Musilová, Ján Deván, Kateřina Amruz Černá et al. · Blood · 2018 · 72 citations · Full text